Michael Entzeroth

Agency for Science, Technology & Research engages in fostering scientific research and development. It is the agency for fostering world-class scientific research and talent for a vibrant knowledge-based and innovation-driven Singapore. The company was founded in 1991 and is headquartered in Singapore.

S*BIO is a privately-held biotech company focused on the research and clinical development of novel targeted small molecule drugs for the treatment of cancer with leading programs around histone deacetylases (HDAC) and kinases. S*BIO's lead candidate, SB939, entered the clinic in 2007. SB1518, S*BIO's potent and orally-active JAK2 inhibitor, entered the clinic in 2008 and has received orphan drug designation from the U.S. FDA. S*BIO has entered into a development collaboration, and option & license agreement with Onyx Pharmaceuticals, Inc. to develop and commercialize SB1518 and its other novel JAK2 inhibitor, SB1578. S*BIO's SB1317, a novel multikinase inhibitor, is in pre-clinical development and under a worldwide exclusive license with Tragara Pharmaceuticals, Inc. for its development and commercialization. In line with its vision to be a leading fully-integrated oncology-focused biotech company in Asia Pacific, S*BIO has established a state-of-the-art R&D infrastructure, complemented by a strong clinical development team. S*BIO has strong links with a network of medical oncologists in Asia Pacific and its investors include EDB Investments' biomedical sciences subsidiary Bio*One Capital, Aravis Ventures, Novartis Bioventures and other international funds. In 2009, S*BIO received the BioSpectrum Editor's Choice, Emerging BioScience Company of Singapore Award.

Part of C.H. Boehringer Sohn AG & Co. KG, Boehringer Ingelheim Pharma GmbH & Co. KG is a pharmaceutical company that manufactures pharmaceutical products. The private company is based in Ingelheim, Germany. The German company was founded in 1885. The CEO is Sabine Nikolaus.

Cennerv Pharmaceuticals Ltd. engages in the pharmaceutical development specializing in CNS disorders with an initial focus on mental health such as depression, insomnia, dementia, schizophrenia and autism. The company was founded on July 13, 2015 and is headquartered in Singapore.